A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative

被引:41
作者
Heaton, JPW [1 ]
Adams, MA [1 ]
Morales, A [1 ]
机构
[1] QUEENS UNIV,DEPT PHARMACOL & TOXICOL,KINGSTON,ON K7L 2V7,CANADA
基金
英国医学研究理事会;
关键词
drug; erectile dysfunction; treatment; penis; impotence;
D O I
10.1038/sj.ijir.3900281
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Aim of the study: A functional classification of treatments for erectile dysfunction is important but none exists at present. Advances in the understanding of the mechanisms of drug action and of the mechanisms of penile erection suggest that there is now a rational basis for a therapeutic classification, with the expectation that a logical diagnostic classification will follow. Methods: The currently available treatments for erectile function and the known relevant basic science were reviewed and assessed. From this, and analysis of classification systems in other fields, a classification was proposed and evaluated with respect to existing treatments. Results: The treatments for erectile dysfunction were classified into five major classes by their mode of action: (I) Central Initiators, (II) Peripheral Initiators, (III) Central Conditioners, (IV) Peripheral Conditioners and (V) Other. Drugs in these classes are further subdivided by the routes of administration and the mechanisms of specificity. Conclusions: It is possible to analyze all known treatments using this classification. The principles of this scheme should be sufficiently clear as to enable knowledgeable specialists to arrive at similar conclusions about a drug. The classification proposed is general enough such that most new drugs should fall within a class. However, it should be modified if necessary, if new therapeutic agents can not be appropriately classified. It is our conclusion that with such endeavours the speciality itself and national regulatory bodies will find it easier to define and control how to apply new drugs, how to evaluate new drugs, and how to establish reasonable equivalences among agents and in whom these drugs and devices should be used.
引用
收藏
页码:115 / 121
页数:7
相关论文
共 18 条
[1]  
[Anonymous], 1971, OXFORD ENGLISH DICT
[2]  
Burrow J. W., 1968, The Origin of Species
[3]   RECOVERY OF ERECTILE FUNCTION BY THE ORAL-ADMINISTRATION OF APOMORPHINE [J].
HEATON, JPW ;
MORALES, A ;
ADAMS, MA ;
JOHNSTON, B ;
ELRASHIDY, R .
UROLOGY, 1995, 45 (02) :200-206
[4]   EFFICACY OF ANTI-SEROTONINERGIC AGENTS IN THE TREATMENT OF ERECTILE DYSFUNCTION [J].
KURT, U ;
OZKARDES, H ;
ALTUG, U ;
GERMIYANOGLU, C ;
GURDAL, M ;
EROL, D .
JOURNAL OF UROLOGY, 1994, 152 (02) :407-409
[5]  
LEWIS RW, 1995, UROL CLIN N AM, V22, P847
[6]   Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction [J].
Linet, OI ;
Ogrinc, FG .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (14) :873-877
[7]   AMS 3-piece inflatable penile prosthesis implantation in men with Peyronie's disease: Comparison of CX and Ultrex cylinders [J].
Montague, DK ;
Angermeier, KW ;
Lakin, MM ;
Ingleright, BJ .
JOURNAL OF UROLOGY, 1996, 156 (05) :1633-1635
[8]   Clinical guidelines panel on erectile dysfunction: Summary report on the treatment of organic erectile dysfunction [J].
Montague, DK ;
Barada, JH ;
Belker, AM ;
Levine, LA ;
Nadig, PW ;
Roehrborn, CG ;
Sharlip, ID ;
Bennett, AH .
JOURNAL OF UROLOGY, 1996, 156 (06) :2007-2011
[9]  
MOOREHEAD A, 1969, DARWIN BEAGLE
[10]   ORAL ANDROGENS IN THE TREATMENT OF HYPOGONADAL IMPOTENT MEN [J].
MORALES, A ;
JOHNSTON, B ;
HEATON, JWP ;
CLARK, A .
JOURNAL OF UROLOGY, 1994, 152 (04) :1115-1118